Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Oncol. 2005 Jul;17(4):361-5.

Adjuvant chemotherapy for soft tissue sarcoma.

Author information

1
Adult Sarcoma Medical Oncology Unit, Istituto Nazionale Tumori, Milano, Italy. paolo.casali@istitutotumori.mi.it

Abstract

PURPOSE OF REVIEW:

To review current state-of-the-art knowledge about adjuvant medical therapy in adult soft tissue sarcomas.

RECENT FINDINGS:

Most recent contributions have added nonrandomized evidence to previously available controlled clinical trials, which were undertaken from the 1970s. Again, results are conflicting, with a limited benefit suggested by some retrospective analyses and denied by others. While a delay in relapse is likely to occur in a fraction of patients treated with adjuvant chemotherapy, a permanent benefit has been more difficult to prove. This result is consistent with findings from previous clinical trials, which pointed to a slight benefit from Doxorubicin-based adjuvant chemotherapy and a possibly higher, although less evidence-based, benefit from anthracycline plus Ifosfamide regimens.

SUMMARY:

Overall, adjuvant chemotherapy may give some benefit in soft tissue sarcoma. If any, it is likely to be of limited degree, confined to the highest-risk patients, and requiring a fully active chemotherapy regimen. This was mainly shown for extremity soft tissue sarcoma but may also apply to other primary sites. The value of molecular-targeted therapy as an adjuvant for high-risk gastrointestinal stromal tumor patients is a different subject awaiting long-term results of ongoing trials.

PMID:
15933469
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center